This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Haas, W.
Right arrow Articles by Morris, T. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Haas, W.
Right arrow Articles by Morris, T. W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, August 2009, p. 3552-3560, Vol. 53, No. 8
0066-4804/09/$08.00+0     doi:10.1128/AAC.00418-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Besifloxacin, a Novel Fluoroquinolone, Has Broad-Spectrum In Vitro Activity against Aerobic and Anaerobic Bacteria{triangledown}

Wolfgang Haas,1* Chris M. Pillar,2 Gary E. Zurenko,3 Jacqueline C. Lee,3 Lynne S. Brunner,1 and Timothy W. Morris1

Bausch & Lomb, Inc., Rochester, New York 14609,1 Eurofins Medinet, Inc., Anti-Infective Services, Chantilly, Virginia 20151,2 Micromyx, 4717 Campus Drive, Kalamazoo, MI 490083

Received 27 March 2009/ Returned for modification 28 April 2009/ Accepted 30 May 2009

The antibacterial spectrum of besifloxacin, a novel fluoroquinolone recently approved for treatment of ocular infections, was studied using 2,690 clinical isolates representing 40 species. Overall, besifloxacin was the most potent agent tested against gram-positive pathogens and anaerobes and was generally equivalent to comparator fluoroquinolones in activity against most gram-negative pathogens. Besifloxacin demonstrated potent, broad-spectrum activity, which was particularly notable against gram-positive and gram-negative isolates that were resistant to other fluoroquinolones and classes of antibacterial agents.

* Corresponding author. Mailing address: Bausch & Lomb, 1400 N. Goodman St., Rochester, NY 14609. Phone: (585) 338-8084. Fax: (585) 338-0277. E-mail: wolfgang.haas{at}bausch.com

{triangledown} Published ahead of print on 8 June 2009.

Antimicrobial Agents and Chemotherapy, August 2009, p. 3552-3560, Vol. 53, No. 8
0066-4804/09/$08.00+0     doi:10.1128/AAC.00418-09
Copyright © 2009, American Society for Microbiology. All Rights Reserved.





Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»